Takeda forecasts $1.7B loss after Shire integration; Flagship's preclinical biotech Axcella closes IPO with $71M+ haul
→ Takeda’s $TAK first set of financial results since consummating its $62 billion acquisition of Shire is in, and it’s giving analysts a negative …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
